|
|
DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant |
|
Vaxjo ID |
101 |
|
Vaccine Adjuvant Name |
DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant |
|
Alternative Names |
Polyester poly (DL-lactide-co-glycolide), PLGA, PLGA microspheres |
|
Adjuvant VO ID |
VO_0001341
|
|
Description |
Poly(lactide-co-glycolic acids) (PLGAs) have been studied most commonly for this purpose because of their proven safety record and established use in marketed products for controlled delivery of several peptide drugs. PLGA microspheres have many desirable features relative to standard aluminum-based adjuvants, including the microspheres' ability to induce cell-mediated immunity, a necessary requirement for emergent vaccines against HIV and cancer (Jiang et al., 2005). |
|
Stage of Development |
Clinical Trial |
|
Safety |
PLGA microspheres and other injectable implants have a long safety record and are used in at least 12 different marketed products from 10 different companies worldwide (Jiang et al., 2005). |
| Related Vaccine(s) |
|
| References |
Byrd and Cassels, 2006: Byrd W, Cassels FJ. The encapsulation of enterotoxigenic Escherichia coli colonization factor CS3 in biodegradable microspheres enhances the murine antibody response following intranasal administration. Microbiology (Reading, England). 2006; 152(Pt 3); 779-786. [PubMed: 16514157].
Jiang et al., 2005: Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Advanced drug delivery reviews. 2005; 57(3); 391-410. [PubMed: 15560948].
|
|
